AUTHOR=Castellví Ivan , Castillo Diego , Corominas Hèctor , Mariscal Anaís , Orozco Sandra , Benito Natividad , Pomar Virginia , Baucells Andrés , Mur Isabel , de la Rosa-Carrillo David , Lobo David , Millan Ana Milena , Hernández de Sosa Nerea , Filella David , Matas Laia , Martínez-Martínez Laura , Juarez Cándido , Casademont Jordi , Domingo Pere TITLE=Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study JOURNAL=Frontiers in Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.973918 DOI=10.3389/fmed.2022.973918 ISSN=2296-858X ABSTRACT=
Coronavirus disease 2019 (COVID-19) has rapidly expanded worldwide. Currently, there are no biomarkers to predict respiratory worsening in patients with mild to moderate COVID-19 pneumonia. Small studies explored the use of Krebs von de Lungen-6 circulating serum levels (sKL-6) as a prognostic biomarker of the worsening of COVID-19 pneumonia. We aimed at a large study to determine the prognostic value of sKL-6 in predicting evolving trends in COVID-19. We prospectively analyzed the characteristics of 836 patients with COVID-19 with mild lung disease on admission. sKL-6 was obtained in all patients at least at baseline and compared among patients with or without respiratory worsening. The receiver operating characteristic curve was used to find the optimal cutoff level. A total of 159 (19%) patients developed respiratory worsening during hospitalization. Baseline sKL-6 levels were not higher in patients who had respiratory worsening (median {IQR} 315.5 {209–469} vs. 306 {214–423} U/ml